false
0001894525
0001894525
2026-09-29
2026-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
September 29, 2026
Apimeds Pharmaceuticals US, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-42545 |
|
85-1099700 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification Number) |
|
100 Matawan Rd, Suite 325
Matawan, New Jersey |
|
07747 |
| (Address of principal executive offices) |
|
(Zip code) |
Registrant’s telephone number, including
area code: (848) 201-5010
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
APUS |
|
NYSE American LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Interim Chief Financial Officer
On September 29, 2026,
Erick Frim notified Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), of his resignation as
Interim Chief Financial Officer of the Company, effective immediately. As previously disclosed, Mr. Frim was reappointed as Interim Chief
Financial Officer on March 30, 2026. Mr. Frim’s resignation was not the result of any disagreement with the Company on any matter
relating to the Company’s operations, policies or practices.
Appointment of
Chief Financial Officer
On September 30, 2026, the Board of Directors
(the “Board”) of the Company appointed Eric Sherb, age 40, as Chief Financial Officer of the Company, effective October
1, 2026.
Mr. Sherb will serve as the Company’s principal
financial officer and principal accounting officer. Mr. Sherb is a Certified Public Accountant with over 18 years of experience in the
capital markets. In January 2019, Mr. Sherb founded EMS Consulting Services, LLC, an accounting and advisory firm, where he has since
served as its Principal. Through EMS Consulting Services, Mr. Sherb has assisted private and public companies via CFO services, complex
technical accounting, U.S. GAAP and SEC reporting, PCAOB audit coordination, IPO readiness, mergers and acquisitions, corporate governance,
and the oversight of accounting and controllership functions. Prior to founding EMS Consulting Services, Mr. Sherb began his career at
PricewaterhouseCoopers LLP in New York before working at mid-market accounting and advisory firms in the capital markets. Mr. Sherb received
his degree from Emory University. Since February 2026, through EMS Consulting Services, Mr. Sherb has also served as fractional Chief
Financial Officer of MindWave Innovations Inc., a wholly owned subsidiary of the Company, an engagement that will terminate in connection
with his appointment.
In connection with his appointment, the Company
entered into an Executive Employment Agreement with Mr. Sherb, effective October 1, 2026 (the “Employment Agreement”).
Under the Employment Agreement, Mr. Sherb will receive a base salary of $60,000 per year.
The compensation described above does not include
any equity-based compensation awards that may be granted to Mr. Sherb in the future under the Company’s equity incentive plan.
There is no arrangement or understanding between
Mr. Sherb and any other person pursuant to which he was selected to this position. There are no transactions involving the Company and
Mr. Sherb that are required to be reported pursuant to Item 404(a) of Regulation S-K. Mr. Sherb has no family relationships with any of
the Board or executive officers of the Company.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Apimeds Pharmaceuticals US, Inc. |
| |
|
| Date: September 30, 2026 |
By: |
/s/ Dr. Vin Menon |
| |
Name: |
Dr. Vin Menon |
| |
Title: |
Co-Chief Executive Officer |
| |
By: |
/s/ SungJoon Chae |
| |
Name: |
SungJoon Chae |
| |
Title: |
Co-Chief Executive Officer & Director |
